EA201791095A1 - Способ лечения рака - Google Patents

Способ лечения рака

Info

Publication number
EA201791095A1
EA201791095A1 EA201791095A EA201791095A EA201791095A1 EA 201791095 A1 EA201791095 A1 EA 201791095A1 EA 201791095 A EA201791095 A EA 201791095A EA 201791095 A EA201791095 A EA 201791095A EA 201791095 A1 EA201791095 A1 EA 201791095A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment method
cancer treatment
inhibitor
ezh2
methods
Prior art date
Application number
EA201791095A
Other languages
English (en)
Inventor
Хайке Кайльхак
Бретт Труитт
Юта Сузуки
Цукаса Мурасе
Футоси Сиката
Original Assignee
Эпизайм, Инк.
ЭИСАИ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпизайм, Инк., ЭИСАИ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. filed Critical Эпизайм, Инк.
Publication of EA201791095A1 publication Critical patent/EA201791095A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Abstract

Изобретение относится к фармацевтическим композициям, содержащим ингибитор(ы) гистонметилтрансферазы EZH2 человека, и способам терапии рака с применением ингибитора(ов) EZH2.
EA201791095A 2014-11-17 2015-11-17 Способ лечения рака EA201791095A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462080985P 2014-11-17 2014-11-17
US201562166572P 2015-05-26 2015-05-26
US201562251903P 2015-11-06 2015-11-06
PCT/US2015/061194 WO2016081523A1 (en) 2014-11-17 2015-11-17 Method for treating cancer

Publications (1)

Publication Number Publication Date
EA201791095A1 true EA201791095A1 (ru) 2017-10-31

Family

ID=56014476

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791095A EA201791095A1 (ru) 2014-11-17 2015-11-17 Способ лечения рака

Country Status (22)

Country Link
US (2) US10786511B2 (ru)
EP (2) EP4272742A1 (ru)
JP (2) JP6829684B2 (ru)
KR (3) KR102644844B1 (ru)
CN (2) CN107249591B (ru)
AU (3) AU2015350108B2 (ru)
BR (1) BR112017010166A2 (ru)
CA (1) CA2967664A1 (ru)
DK (1) DK3220916T3 (ru)
EA (1) EA201791095A1 (ru)
ES (1) ES2947819T3 (ru)
FI (1) FI3220916T3 (ru)
HU (1) HUE062159T2 (ru)
IL (3) IL296080B2 (ru)
LT (1) LT3220916T (ru)
MX (2) MX2017006089A (ru)
NZ (1) NZ731696A (ru)
PL (1) PL3220916T3 (ru)
PT (1) PT3220916T (ru)
SG (1) SG11201703806XA (ru)
SI (1) SI3220916T1 (ru)
WO (1) WO2016081523A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282741B2 (en) 2013-12-06 2024-01-01 Epizyme Inc Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer
KR20230031963A (ko) 2014-06-17 2023-03-07 에피자임, 인코포레이티드 림프종 치료를 위한 ｅｚｈ2 억제제
SG10201902664RA (en) 2015-04-20 2019-04-29 Epizyme Inc Combination therapy for treating cancer
JP6890097B2 (ja) 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
CN108025191A (zh) 2015-08-24 2018-05-11 Epizyme股份有限公司 治疗癌症的方法
EP3407978A4 (en) 2016-01-29 2020-01-15 Epizyme Inc COMBINATION THERAPY FOR TREATING CANCER
AU2017273726B2 (en) 2016-06-01 2023-10-19 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
BR112019014924A2 (pt) 2017-01-19 2020-03-31 St. Marianna University School Of Medicine Composição farmacêutica usada para o tratamento de mielopatia associada ao htlv-1
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
CN110944628A (zh) 2017-06-02 2020-03-31 Epizyme股份有限公司 使用ezh2抑制剂治疗癌症
WO2019050924A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
JP2022167451A (ja) 2021-04-23 2022-11-04 日立Astemo株式会社 情報処理装置、情報処理方法、プログラムおよび記憶媒体
WO2023159124A2 (en) * 2022-02-17 2023-08-24 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
TW202400140A (zh) 2022-04-27 2024-01-01 日商第一三共股份有限公司 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070026064A1 (en) * 2005-07-29 2007-02-01 Yoder Steven L Pharmaceutical dosage forms having watermark-type identification and authentication inditia
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
KR102061353B1 (ko) 2010-09-10 2020-01-02 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012097222A1 (en) * 2011-01-14 2012-07-19 Bristol-Myers Squibb Company High drug load tablet formulation of brivanib alaninate
AU2012223448B2 (en) 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
KR102453519B1 (ko) 2012-03-12 2022-10-11 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
DK3184523T3 (da) * 2012-04-13 2019-08-19 Epizyme Inc N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4' -(morphofinomethyl)-[1,1'-biphenyl]-3-carboxamidhydrobromid til anvendelse i behandlingen af en sygdom med celleproliferation i det hæmatologiske system.
IL289300B1 (en) * 2012-04-13 2024-01-01 Epizyme Inc Combined treatment for cancer
LT2908823T (lt) * 2012-10-15 2019-10-25 Epizyme Inc Vėžio gydymo būdai
UA115074C2 (uk) 2012-10-15 2017-09-11 Епізайм, Інк. Бензольні сполуки, що містять замісники
US20150313906A1 (en) * 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
US20150344427A1 (en) 2012-12-21 2015-12-03 Epizyme, Inc. 1,4-pyridone compounds
US9701666B2 (en) 2012-12-21 2017-07-11 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
CA2903572A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
WO2014144747A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015010049A1 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
KR102142177B1 (ko) * 2013-10-16 2020-08-07 에피자임, 인코포레이티드 Ezh2 억제용 하이드로클로라이드 염 형태
WO2015058125A1 (en) * 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
IL282741B2 (en) 2013-12-06 2024-01-01 Epizyme Inc Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer
KR20230031963A (ko) * 2014-06-17 2023-03-07 에피자임, 인코포레이티드 림프종 치료를 위한 ｅｚｈ2 억제제
WO2015200650A1 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
CN112168967A (zh) 2014-10-16 2021-01-05 Epizyme股份有限公司 治疗癌症的方法
JP6890097B2 (ja) * 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
US11147819B2 (en) * 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer

Also Published As

Publication number Publication date
KR102644844B1 (ko) 2024-03-07
CA2967664A1 (en) 2016-05-26
EP3220916A4 (en) 2018-07-11
KR20240035908A (ko) 2024-03-18
EP4272742A1 (en) 2023-11-08
BR112017010166A2 (pt) 2018-02-14
US20170360797A1 (en) 2017-12-21
SG11201703806XA (en) 2017-06-29
MX2021006734A (es) 2021-07-02
AU2021204706B2 (en) 2023-11-23
KR20210156840A (ko) 2021-12-27
JP6829684B2 (ja) 2021-02-10
IL304252A (en) 2023-09-01
DK3220916T3 (da) 2023-06-26
CN107249591A (zh) 2017-10-13
IL252182A0 (en) 2017-07-31
ES2947819T3 (es) 2023-08-21
IL296080B1 (en) 2023-08-01
JP2023062189A (ja) 2023-05-02
KR20170103768A (ko) 2017-09-13
KR102338802B1 (ko) 2021-12-14
HUE062159T2 (hu) 2023-10-28
FI3220916T3 (fi) 2023-06-19
LT3220916T (lt) 2023-07-25
AU2021204706A1 (en) 2021-07-29
IL296080B2 (en) 2023-12-01
NZ731696A (en) 2024-03-22
US10786511B2 (en) 2020-09-29
CN116650500A (zh) 2023-08-29
WO2016081523A1 (en) 2016-05-26
AU2015350108B2 (en) 2021-04-08
JP2021073241A (ja) 2021-05-13
JP2017537899A (ja) 2017-12-21
IL296080A (en) 2022-11-01
SI3220916T1 (sl) 2023-09-29
CN107249591B (zh) 2024-01-30
PT3220916T (pt) 2023-06-26
AU2024201171A1 (en) 2024-03-14
IL252182B (en) 2022-10-01
MX2017006089A (es) 2017-12-11
AU2015350108A1 (en) 2017-05-25
EP3220916B1 (en) 2023-04-19
EP3220916A1 (en) 2017-09-27
US20210060030A1 (en) 2021-03-04
IL252182B2 (en) 2023-02-01
PL3220916T3 (pl) 2023-08-14

Similar Documents

Publication Publication Date Title
EA201791095A1 (ru) Способ лечения рака
EA201890567A1 (ru) Способ лечения рака
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
MX2020003702A (es) Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1).
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201591599A1 (ru) Ингибиторы ido
EA201691134A1 (ru) Новые ингибиторы глутаминазы
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
GB2541571A (en) Pharmaceutical compositions
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201791736A1 (ru) Комбинированная терапия для лечения рака
PH12018502154A1 (en) Methods of treating ocular conditions
EA201992137A1 (ru) ПИРИМИДОПИРИМИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ Wee-1
EA201790565A1 (ru) Композиции и способы для лечения предраковых поражений кожи
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
ZA201703467B (en) Methods of treating ocular conditions
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
EA201691896A1 (ru) Соединения и способы их применения